fashion -WSS

fashion

author：focus 2025-09-04 21:59:08 - browse：74122

SAN DIEGO — One of the toughest subtypes of acute leukemia involves a genetic alteration in the KMT2A gene. Many cancers with this genetic alteration end up relapsing or don’t respond to treatment, but new data presented at the annual American Society of Hematology meeting offer hope of a new targeted therapy for these patients.

The study, called the Phase 2 Augment-101 trial, tested Syndax’s revumenib in patients with relapsed or refractory leukemia with these KMT2A genetic rearrangements. Overall, about 63% of the patients responded to the treatment, with many able to receive a potentially curative stem cell transplant later on, which is often the ultimate goal for patients with relapsed or refractory patients, said Ibrahim Aldoss, a hematologist-oncologist at City of Hope and the study’s presenter, in an interview.

“KMT2A-rearranged diseases represent 10% of all leukemia. They can be exceptionally hard to treat,” Aldoss said. “The median overall survival remains low with current available treatment. Right now there’s no targeted therapy for KMT2A-rearranged disease. We’re really excited about revumenib as it targets the mutation, and we’re seeing encouraging outcomes.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Would Medicare drug price negotiations stall in a shutdown?

focus

hotspot

WSS

Histogen: Failed biotech offers rare public look inside

FDA seeks to regulate lab

Phenylephrine and the overlooked value of the placebo effect

How one patient went off dialysis — and others can too

Why do women spend more than men on medical expenses?

Medicare drug price negotiation program allowed for now

entertainment

fashion

hotspot

Psychedelics group wrestles with new pharma identity

Researchers use wearables data and AI to predict preterm birth risk

Guidelines to prevent youth baseball injuries need more muscle

After a drawn out lobbying fight, ARPA

The cancer drug shortage isn’t new — and neither are the solutions

A Q&A with the global head of Boehringer Ingelheim's innovation unit

Medical records are filled with copy

Paxlovid should be available without a positive Covid test

How one medical school became remarkably diverse

Menendez indictment could see pharma lose a key ally

hotspot

FDA rejects Alnylam's heart disease treatment over insufficient data

Why do women spend more than men on medical expenses?

How the Dana

FDA advisers vote against ALS treatment from BrainStorm

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

Would Medicare drug price negotiations stall in a shutdown?

Wikipedia

focus

hotspot

focus